ArticleClinical and experimental medicine2026
Integrated transcriptomic analysis identifies an AKT1-associated metabolic-inflammatory signature in osteoporosis.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a significant global health challenge, and low bone mineral density (Low-BMD) is a major clinical feature and risk indicator of osteoporosis. Fatty acid metabolism has been increasingly implicated in bone remodeling and inflammatory regulation, but the transcriptomic links between fatty acid metabolism and immune-inflammatory alterations in Low-BMD remain unclear. We integrated three GEO datasets, including 60 High-BMD controls and 59 Low-BMD subjects. Differential expression analysis, immune infiltration analysis, NMF clustering, WGCNA, pseudotime analysis, and machine learning were performed to identify fatty acid metabolism-related genes associated with Low-BMD. AKT1 knockdown was used to evaluate its potential role in regulating inflammatory mediators. Eighteen fatty acid metabolism-related differentially expressed genes were identified between High-BMD and Low-BMD samples and were enriched in inflammatory, immune, and osteoclast-related pathways. NMF clustering revealed two Low-BMD molecular subtypes with distinct metabolic and immune-inflammatory features. Machine learning identified an AKT1-containing diagnostic signature with good predictive performance, and AKT1 was positively correlated with inflammatory response scores and inflammatory markers. Quantitative Real-time PCR confirmed Akt1 knockdown, and ELISA showed reduced IL-6, TNF-α, and IL-1β secretion in MC3T3-E1 cells. AKT1 may serve as a fatty acid metabolism-related candidate gene associated with immune-inflammatory remodeling and inflammatory mediator regulation in Low-BMD. These findings suggest a potential AKT1-associated metabolic-inflammatory regulatory relationship and provide candidate biomarkers for future validation in osteoporosis-related bone loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.